• Vaccine Name: L. major synthetic DNA vaccine IDM2
• Target Pathogen: Leishmania major
• Target Disease: Cutaneous leishmaniasis
• Type: DNA vaccine
• Status: Research
• Host Species for Licensed Use: Human
• Host Species as Laboratory Animal Model: mouse
• Antigen: PEPCK - dominant naturally processed peptide that elicits strong CD4(+) T cell responses in infected mice and humans(Mou et al., 2015)
• PEPCK gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• Immunization Route: Intradermal injection (i.d.)

Mouse Response

• Host Strain: C57BL/6
• Vaccination Protocol: Performed intramuscular DNA delivery of either IDM2 or PB in C57BL/6 mice at a dose of 20 μg each, followed by EP, two times, 2 weeks apart(Louis et al., 2019)
• Immune Response: Both mice vaccinated with IDM2 and those vaccinated with PB mounted a robust immune response, with avereages of 2500 SFU/million and 3700 SFU/million splenocytes against IDM2 and PB, respectively. A greater number of CD4+ T cells responded to peptides in pool 1 of PB than in pool 1 of IDM2.(Louis et al., 2019)
• Immune Response Assay Type: Enzyme-linked immunosorbent spot (ELISpot) assay
• Challenge Protocol: Immunized mice twice, at a 2 week interval, by either i.m. or i.d. EP. flank or TA skin from vaccination and contralateral sites was harvested spleens 45 days after the final vaccination.